
Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target
Rhythm Pharmaceuticals (RYTM) Analyst Ratings
Bulls say
Rhythm Pharmaceuticals is positioned for durable growth because IMCIVREE is gaining traction in acquired hypothalamic obesity, with 3Q26 revenue of $92.1M, U.S. sales of $67.5M, and more than 700 patient start forms supported by expanding access and over 500 prescribers. Its outlook is further strengthened by an accretive LG Chem royalty buydown that cuts MC4R royalties to a flat 1% and by a $750M term loan facility that adds non-dilutive capital while preserving flexibility, with $320.9M in cash at 3Q26 and funding for at least 24 months. Beyond the launch, the company has multiple upside drivers from bivamelagon and RM-718, including planned Phase 3 PWS development in 2027 and Japan and Europe expansion, which broadens the long-term MC4R franchise opportunity.
Bears say
Rhythm Pharmaceuticals is facing a cautious fundamental setup because downside risk is concentrated in launch execution, with delays in outside-U.S. aHO launches and slower-than-anticipated uptake or reimbursement capable of materially pressuring revenue growth. The outlook is also weakened by execution risk around its next-generation MC4R programs, since delays or failure to develop competitive bivamelagon and RM-718 would leave the company overly dependent on IMCIVREE and limit long-term product diversification. Near-term estimates for 2027 and 2028 were reduced as topline was trimmed for a slower launch trajectory and operating expense increased, mainly due to milestone payments owed to LG Chem after the royalty amendment.
This aggregate rating is based on analysts' research of Rhythm Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Rhythm Pharmaceuticals (RYTM) Analyst Forecast & Price Prediction
Start investing in Rhythm Pharmaceuticals (RYTM)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Rhythm Pharmaceuticals (RYTM) Forecast
Rhythm Pharmaceuticals (RYTM) Analyst Forecast & Price Prediction
Start investing in Rhythm Pharmaceuticals (RYTM)
Order type
Buy in
Order amount
Est. shares
0 shares